证券代码：300676 证券简称：华大基因 公告编号：2025-039 注：本次质押股份不涉及负担重大资产重组等业绩补偿义务。 （二）控股股东及其一致行动人股份累计质押情况 一、控股股东及其一致行动人部分股份质押的基本情况 | | 是否为控股 股东或第一 | 本次质押数 | 占其所持 | | 是否为限 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 占公司 | 售股（如 | 是否为 | 质押起 | 质押到期 | | 质押用 | | 股东名称 | 大股东及其 | 量（股） | 股份比例 | 总股本 | 是，注明 | 补充质 | 始日 | 日 | 质权人 | 途 | | | 一致行动人 | | | 比例 | 限售类 | 押 | | | | | | | | | | | 型） | | | | 中国邮政 | | | | | | | | | | | 至办理解 | 储蓄银行 | 自身生 | | 深圳华大 | | | | | | | | | | | | 基因科技 | 是 | | | | 否 | ...

证券代码：300676 证券简称：华大基因 公告编号：2025-038 深圳华大基因股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司控股股东 深圳华大基因科技有限公司（以下简称华大控股）的通知，获悉华大控股将其持有的 部分公司股份办理了质押，相应的质押登记手续已通过中国证券登记结算有限责任 公司深圳分公司办理完毕。现将具体事项公告如下： 一、控股股东及其一致行动人部分股份质押的基本情况 | | 是否为控股 股东或第一 | 本次质押数 | | | 是否为限 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 占其所持 | 占公司 | 售股（如 | 是否为 | 质押起 | 质押到期 | | 质押用 | | 股东名称 | 大股东及其 | 量（股） | 股份比例 | 总股本 | 是，注明 | 补充质 | 始日 | 日 | 质权人 | 途 | ...

6月10日， 华大基因 发布华大肿瘤用药与遗传分析知识库——遗传性肿瘤变异知识库和肿瘤体细胞变异 与用药知识库，填补了国内肿瘤精准诊疗数据产品空白，打造国内基于真实世界基因 大数据 的医疗知 识库范例。 此外，华大基因与深圳数据交易所正式达成战略合作，致力于数据产品创新孵化、行业数据标准建设、 数据合规安全、数据资产金融化以及数据空间建设等关键领域。 华大基因CEO赵立见在发布会前接受了记者的采访，分享了华大基因近年来如何超前布局，积极应 对"卡脖子"问题，探索变数据资源为数据资产，主动迎接 人工智能 为生命科学带来的机遇与挑战。 激活医疗 数据要素 乘数效应 提升中国基因检测产业 全球影响力 展望未来，赵立见告诉记者，华大基因将以肿瘤防控为起点，向生育健康、传染病防控、慢性病管理、 133111i主动健康管理新范式四大核心领域延伸，目标是通过数据整合，实现"防诊治康"全链路覆盖。 据赵立见介绍，"遗传性肿瘤变异知识库"覆盖了170多个基因、19万个变异，专注于遗传性肿瘤的早筛 与遗传咨询；"肿瘤体细胞变异与用药知识库"则整合了3000多个基因、2000余种药物及5万多个变异， 为精准用药决策提供科学依据。 ...

证券代码：300676 证券简称：华大基因 公告编号：2025-037 近日，公司已完成注册地址的工商变更登记手续以及《公司章程》的工商备 案手续，公司注册地址由"深圳市盐田区洪安三街21号华大综合园7栋7层-14层" 变更为"深圳市盐田区梅沙街道滨海社区云华路9号华大时空中心B栋8南1-1"， 并取得了深圳市市场监督管理局换发的《营业执照》。同时，根据工商登记机关 最终核准的注册地址对《公司章程》进行相应条款的修订。 除上述注册地址变更的修订条款外，《公司章程》其他条款内容不变。 三、备查文件 1、《深圳华大基因股份有限公司营业执照》； 2、深圳市市场监督管理局出具的变更登记和换发证照通知书。 深圳华大基因股份有限公司 关于完成注册地址变更并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、公司注册地址变更的情况说明 深圳华大基因股份有限公司（以下简称"公司"）分别于2025年4月24日、2025 年5月20日召开第四届董事会第五次会议、2024年年度股东会，审议通过《关于变 更注册地址并修订<公司章程>的议案》。具体内容详见公司于20 ...

Group 1 - The 11th China (Shanghai) International Technology Import and Export Fair has attracted nearly a thousand exhibitors from around 20 countries and regions, showcasing innovative achievements and building an international technology cooperation network [1] - The United Nations Industrial Development Organization emphasizes support for technology innovation and transfer, focusing on green transformation, digital technology, artificial intelligence, and South-South cooperation as priority areas [1] - Glasgow, as the overseas guest city, aims to strengthen cooperation with China in clean energy, particularly in offshore wind power, highlighting the fair's focus on green low-carbon and medical technology sectors [1] Group 2 - The Peru exhibition team is interested in collaborating in agriculture, manufacturing, irrigation, and mining technology, benefiting economically and socially from deep cooperation with China [2] - Shenzhen serves as the domestic guest city, with BGI showcasing its "GenSIRO-16" AI-based high-throughput gene testing solution, having established partnerships with over 3,000 overseas medical and research institutions [2] - Shanghai's technology import and export contract amount has seen an average annual growth of 8.6% since the 14th Five-Year Plan, with a projected amount of $21.33 billion in 2024, marking a 17.7% year-on-year increase and setting a historical record [2]

Core Viewpoint - BGI Genomics has officially established a strategic partnership with the Shenzhen Data Exchange, launching its first comprehensive tumor database, marking a significant step towards transforming into a data-driven intelligent medical ecosystem [2][9]. Group 1: Strategic Cooperation - The partnership aims to deepen collaboration in key areas such as data product innovation, industry data standard construction, data compliance and security, financialization of data assets, and data space development [2]. - BGI Genomics is transitioning from a traditional genetic testing service provider to a data-driven intelligent medical ecosystem, leveraging its proprietary platform and technological advantages to build a comprehensive database reflecting the genetic characteristics of the Chinese population [9][11]. - The cooperation is seen as a critical move to construct an autonomous data ecosystem and implement the national strategy of "data elements × healthcare" [9]. Group 2: Industry Context - The global precision medicine market is experiencing rapid growth, and China's data element market reform is making significant breakthroughs, with Shenzhen leading the way by establishing a data exchange and regulatory framework for compliant data circulation [4][5]. - The collaboration is positioned as a key starting point for the value development of genetic data, aiming to explore innovative paths for compliant development and application of genetic data [11]. - The initiative addresses critical industry challenges such as data security, privacy protection, and complex regulatory compliance, providing a systematic framework to enhance overall governance in the sector [13]. Group 3: Product Launch - BGI Genomics has launched a gene data product, the comprehensive tumor database, which integrates authoritative global genetic variation and treatment data while focusing on clinical guidelines and practice data unique to China [13]. - This product aims to provide high-value data services for precision medicine research and alleviate challenges associated with reliance on international databases [13].

Group 1 - Medical device sector shows strong performance with ETF fund (159797) experiencing significant trading volume and net inflow of funds [1] - Recent policy document issued on June 9 aims to improve healthcare resources and insurance mechanisms, which is seen as a major driver for pharmaceutical companies [3] - Citic Securities predicts a trend of low-to-high earnings growth in the medical device sector, with significant improvements expected in the second half of the year [4] Group 2 - Structural investment opportunities exist within the medical device sector, with certain companies expected to achieve high growth in Q2 and Q3 [5] - The easing of US-China tariffs is beneficial for medical device companies, potentially lowering production costs and expanding overseas market share [6] - The medical device ETF fund (159797) covers core areas such as medical equipment and in vitro diagnostics, with top ten weighted stocks accounting for 46.78% [6][7]

重要内容提示： 1、本次归属股票上市流通日：2025 年 6 月 11 日（星期三）； 2、本次归属人数：421 人（首次授予与预留授予归属人数存在部分重合）， 其中，首次授予部分第二个归属期归属人数为 417 人；预留授予部分第一个归属 期归属人数为 18 人； 深圳华大基因股份有限公司 关于 2022 年限制性股票激励计划首次授予部分第二个归属期及 预留授予部分第一个归属期归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 证券代码：300676 证券简称：华大基因 公告编号：2025-036 一、本激励计划实施情况概要 （一）本激励计划简述及授予情况 1 3、本次归属股票数量：249.55 万股，占公司目前总股本的 0.60%；其中，首 次授予部分第二个归属期归属股票数量 179.55 万股，预留授予部分第一个归属期 归属股票数量 70 万股； 4、本次归属的限制性股票授予价格（调整后）：27.73 元/股； 公司于 2022 年 11 月 18 日、2022 年 12 月 6 日分别召开第三届董事会第十三 次会议、2022 年第五 ...

Group 1 - The assisted reproductive concept sector increased by 3.33%, ranking 10th among concept sectors, with 68 stocks rising, including Haichen Pharmaceutical which hit a 20% limit up, and others like Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical also reaching their limit up [1][2] - Notable gainers in the assisted reproductive sector included Xinghao Pharmaceutical, Shengnuo Biological, and Saiseng Pharmaceutical, which rose by 27.29%, 17.58%, and 6.08% respectively [1][6] - The sector saw a net inflow of 414 million yuan from main funds, with 31 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow, led by Zhongsheng Pharmaceutical with a net inflow of 247 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio in the assisted reproductive sector were Zhongsheng Pharmaceutical at 55.08%, Shuanglu Pharmaceutical at 20.11%, and Meinuo Pharmaceutical at 17.33% [3][4] - The trading volume and turnover rates for leading stocks in the sector were significant, with Zhongsheng Pharmaceutical showing a daily increase of 9.99% and a turnover rate of 3.84% [3][4] - Other stocks with notable performance included Fuxing Pharmaceutical with a 3.60% increase and a turnover rate of 2.17%, and Meinuo Pharmaceutical with a 9.97% increase and a turnover rate of 7.37% [3][4]

Group 1 - The core viewpoint of the news highlights the recent surge in the rare earth permanent magnet sector, driven by export control measures and market dynamics [1][2] - The A500 Index ETF (159351) has shown a positive performance, with a 0.62% increase and a trading volume exceeding 2 billion yuan, indicating strong investor interest [1][2] - The rare earth industry is experiencing a supply tightening and price stabilization, with expectations for moderate price increases benefiting equity sector profitability [2] Group 2 - The A500 Index ETF closely tracks the CSI A500 Index, which includes 500 representative stocks across various industries, balancing large-cap stocks with core industry leaders [2] - The A-share market is seen as having the potential for a bull market, driven by increasing household asset allocation towards equities and improvements in corporate governance and shareholder returns [3] - The overall profitability of Chinese enterprises is expected to rise, with a historical supply clearing cycle anticipated, indicating a shift towards higher value sectors [3]